| Ytd | -25.36% | |
| 1y | -50.48% |
| Open | 1.56 | Prev Close | 1.57 | Low | 1.53 | High | 1.59 | Mkt Cap | 59.28M |
| Vol | 46.14K | Avg Vol | 99.61K | EPS | -0.05 | P/E | -30.78 | Forward P/E | N/A |
| Beta | 0.04 | Short Ratio | 4.64 | Inst. Own | 2.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.57 | 200-d Avg | 1.84 | 1yr Est | 7.00 |
OKYO News
OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigati
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
Market breadth continues to improve, even if it has pulled back lately, according to Adam Turnquist,
Walt Disney Co (NYSE:DIS, XETRA:WDP) is scheduled to report fiscal third quarter results on August 5
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F f
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F f
Delta Air Lines Inc (NYSE:DAL) reaffirmed its full-year earnings outlook despite higher fuel costs,
US banks could deliver broad earnings beats as strong capital markets activity, resilient economic c
First Hawaiian, Inc. (NASDAQ:FHB) has agreed to acquire TriCo Bancshares (NASDAQ:TCBK), a combinatio
HC Wainwright & Co. analyst Yi Chen maintains OKYO Pharma (NASDAQ:OKYO) with a Buy and lowers
Taiwan Semiconductor Manufacturing Co (ADR) (NYSE:TSM) reported record June revenue of NT$442.7 bill
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting w
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting w
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company
Gainers Mobile Global Esports Inc. (NASDAQ: MGAM) shares surged 103.9% to settle at $5.30 on Tues
On Tuesday, 540 companies set new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.